For targeting the non-immunogenic cancer cells, the adoptive transfer of genetically engineered CD8+ T cells has been emerged as an attractive approach to exert effective tumoricidal ability via the expression of chimeric antigenic receptors (i.e., CAR-T cells). Here, CD8A is linked to cancer.